Cat. # | Size | Qty. | Price |
---|---|---|---|
24876T | 1 Kit (6 x 20 microliters) |
|
Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
---|---|---|---|---|---|
SQSTM1/p62 (D5E2) Rabbit mAb 8025 | 20 µl |
|
H Mk | 62 | Rabbit IgG |
TRAF6 (D21G3) Rabbit mAb 8028 | 20 µl |
|
H Mk | 60 | Rabbit IgG |
K63-linkage Specific Polyubiquitin (D7A11) Rabbit mAb 5621 | 20 µl |
|
All | Rabbit IgG | |
TrkA (12G8) Rabbit mAb 2510 | 20 µl |
|
H | 140 | Rabbit IgG |
NRF2 (D1Z9C) XP® Rabbit mAb 12721 | 20 µl |
|
H M Mk | 97-100 | Rabbit IgG |
KEAP1 (D6B12) Rabbit mAb 8047 | 20 µl |
|
H M R | 60-64 | Rabbit IgG |
Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Goat |
Product Information
Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly162 of human SQSTM1/p62 protein, residues near the amino terminus of human TRAF6 protein, residues surrounding the Lys63 branch of the human diubiquitin chain, residues surrounding Arg220 of human TrkA, residues surrounding Ala275 of human NRF2 protein, and residues near the carboxy terminus of human KEAP1 protein.
Sequestosome 1 (SQSTM1, p62) is a ubiquitin binding protein involved in cell signaling, oxidative stress, and autophagy (1-4). It was first identified as a protein that binds to the SH2 domain of p56Lck (5) and independently found to interact with PKCζ (6,7). SQSTM1 was subsequently found to interact with ubiquitin, providing a scaffold for several signaling proteins and triggering degradation of proteins through the proteasome or lysosome (8). Interaction between SQSTM1 and TRAF6 leads to the K63-linked polyubiquitination of TRAF6 and subsequent activation of the NF-κB pathway (9). Protein aggregates formed by SQSTM1 can be degraded by the autophagosome (4,10,11). SQSTM1 binds autophagosomal membrane protein LC3/Atg8, bringing SQSTM1-containing protein aggregates to the autophagosome (12). Lysosomal degradation of autophagosomes leads to a decrease in SQSTM1 levels during autophagy; conversely, autophagy inhibitors stabilize SQSTM1 levels. SQSTM1 also interacts with KEAP1, which is a cytoplasmic inhibitor of NRF2, a key transcription factor involved in cellular responses to oxidative stress (3). Under basal conditions, KEAP1 binds and retains NRF2 in the cytoplasm where it can be targeted for ubiquitin-mediated degradation (13). Small amounts of constitutive nuclear NRF2 maintain cellular homeostasis through regulation of basal expression of antioxidant response genes. Following oxidative or electrophilic stress, KEAP1 releases NRF2, thereby allowing the activator to translocate to the nucleus and bind to ARE-containing genes (14). The coordinated action of NRF2 and other transcription factors mediates the response to oxidative stress (15). Thus, accumulation of SQSTM1 can lead to an increase in NRF2 activity (3). KEAP1 also targets the down regulation of NF-κB activity by targeting IKKβ degradation (16). TrkA is a member of Trk receptor tyrosine kinases and is activated by NGF, which stimulates TrkA polyubiquitination (17,18). TrkA regulates proliferation and is important for development and maturation of the nervous system (19). SQSTM1 interaction with TRAF6 controls synthesis of K63 polyubiquititination on TrkA (18, 20). TrkA polyubiquitination is essential for neurotrophin-dependent receptor internalization, cell differentiation, and signaling (18).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.